Our focus is on products and technologies that will improve the management of cardiovascular disease.
A strategic focus on cardiovascular technology
For more than a decade, Hydrix has been at the forefront of developing new cardiovascular technology for clients who are developing total artificial hearts and heart pump devices.
Cardiovascular disease (CVD) is the world’s leading cause of death. It afflicts 14% of the global population. As such, the devices market is expected to grow to US$70B by 2027. This represents a large & growing market opportunity for Hydrix.
We are building on 20 years of experience in medtech product development to translate this know how into establishing Hydrix as a leading cardiovascular technology company.
Ambulatory Monitoring Devices
$3.8 B
Global Market 2020
Estimated 2027
$6.7 B
Interventional
Devices
$17.5 B
Global Market 2020
Estimated 2027
$26.8 B
Cardiac Rhythm Management
$20.4 B
Global Market 2020
Estimated 2027
$31.2 B
Cardiovascular Surgery Devices
$1.9 B
Global Market 2020
Estimated 2027
$2.1 B
Our cardiovascular mission
In our pursuit of growing our cardiovascular market share, we are focusing on building out our capabilities and reputation, our market insights, growing and maturing key aspects of our business
Product development leadership
Hydrix is internationally recognised as the company of choice for developing control systems for Mechanical Circulatory Support devices (MCS) including Total Artificial Hearts (TAH), MiniPumps and Ventricular Assist Devices (VAD). We work with for medical companies in the US, EU and Australia, from start-ups to SMEs, helping them progress their technologies from the lab bench to animal trials, first-in-human trials and ultimately, market release.
Hydrix was also recently recognised with an International Good Design Award for our unique LUDO system, a platform technology that de-risks and accelerates client MCS programs, providing them with greater confidence in reaching their desired outcome. Learn more about LUDO
